ALIMTAS BIOVENTURES

LIFE SCIENCE ENTREPRENEURSHIP

Alimtas works directly with the Office of Technology Licensing to spin out Princeton University life science discoveries spanning biotechnology, therapeutics, medical technologies, and other subfields from researchers through rigorous due diligence and business planning. Alimtas also partners with leading life science venture capital firms and industry companies to deepen members’ knowledge, methodologies, and networks.

DIRECTORS

Mary Shim ‘28

Hi! I’m Mary, a sophomore from Houston, TX majoring in Neuroscience with minors in Global Health & Health Policy and Bioengineering. Outside of Alimtas, I serve as the Assistant Director of Executive Relations for Business Today’s International Conference, volunteer through music initiatives, and love restaurant-hopping or exploring the city with my friends. Excited to be working with you all!"

Contact

Mahdi Bhalloo ‘28

Hi there! My name is Mahdi Bhalloo, and I’m a junior here at Princeton studying neuroscience on a pre-medical track. I am deeply passionate about advancing the field of medical technology forward by taking novel research findings and turning them into commercialized products.

Contact

Oscair Page, MOL ‘26

I’m a senior in the molecular biology department minoring in COS and bioengineering. I’ve had an interest in biotechnology since starting at Princeton but have always found it to be a somewhat inaccessible industry, especially for undergrads. E-Club - and Alimtas in particular - has opened doors for me and exposed me to a side of biotech that I didn’t expect to see so early. I joined the club with minimal experience in entrepreneurship but have since developed a real passion for the field, especially in the context of biotech. I’m really excited to be co-directing Alimtas this year and hope to use the position to foster a more robust biotech startup culture on campus while preparing myself for a career closely linked to the industry.

Contact

what we do

  • Through partnership with Office of Technology Licensing, we receive a new key piece of Princeton IP/Technology in the life sciences to work on every semester

  • We conduct a deep dive on the technology and current research to understand the competitive landscape

  • We assess commercialization pathways, which include clinical trial requirements, potential partnerships, funding requirements and opportunities, and licensing opportunities

  • At the end of the semester, we provide a deliverable presentation and comprehensive business plan detailing how the business can be formed and the product brought to market

HIGHLIGHTS

2020-21 (SPRING)

2020-21 (FALL)

2019-2020

The team created a pitch deck about a gene therapy promoter for increased genetic payload and long term expression invented by Professor Esteban Engel (NEU) and will be pitching the deck to leaders in the field in the early Fall Semester (Sep. 2021).

The team finalized a licensing deal for a high-throughput SARS-CoV-2 replicon model invented by Professor Alexander Ploss (MOL) and virtually pitched the deck to multiple biotechnology companies and venture capital firms, collecting invaluable feedback along the way (Dec. 2020).

The team created a complete pitch deck for Professor Alexander Ploss of Molecular Biology’s novel HBV technology and successfully pitched the deck to leaders in the field, collecting valuable feedback along the way (Dec. 2019)

our partners

Princeton Innovation Center BioLabs | Princeton Office of the Dean of Undergraduate Students | Princeton Entrepreneurship Council | Princeton Office of Technology Licensing | New Jersey Health Foundation | Keller Center for Innovation in Engineering Education | Merck | Regeneron | Gilead | Alynylam | Eli Lilly